Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse
ConclusionConsidering the fact that gene polymorphisms could significantly affect pathophysiology of hematological malignancies, these genetic changes may be considered as potential prognostic biomarkers and therapeutic agents in these disorders. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 22, 2018 Category: Cancer & Oncology Source Type: research

ASCO 2018 NSCLC highlights —combination therapy is key
SummaryNon-small cell lung cancer (NSCLC) treatment was booming at this year ’s ASCO 2018 meeting as several well-performed phase III trials with practice-changing potential were presented. Thereby immune checkpoint blockade (ICB) consolidated its major role in the treatment of NSCLC patients without genetic alterations and extended its use by showing impressive data on I CB combination therapies (mainly combined with chemotherapy). Furthermore the role of predictive biomarkers for ICB therapy (Programmed death-ligand 1 [PD-L1] expression, tumor mutational burden [TMB] testing and others) have been further ...
Source: Memo - Magazine of European Medical Oncology - October 22, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease:  how to manage and who is the right patient in colorectal cancer?
SummaryMetastatic colorectal cancer was long considered for palliative therapy, until significant improvement in surgical techniques and more effective chemotherapeutic regimens changed the way metastatic colon cancer patients are being treated today. Prospective trials were designed to answer the question which patient with metastatic disease could potentially be cured by a  multidisciplinary approach with medical oncologists, surgeons and radiation oncology using an induction chemotherapy in combination with a targeted agent and being monitored for resectability in multidisciplinary tumor boards. Patients with ...
Source: Memo - Magazine of European Medical Oncology - October 22, 2018 Category: Cancer & Oncology Source Type: research

Kaposi sarcoma following autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia
ConclusionEven though the mortality rate is low with Kaposi sarcoma, it can cause physical and psychological burden for the patients. Additional investigations and raising awareness of Kaposi sarcoma while evaluating the differential diagnosis of skin lesions in chronic lymphocytic leukemia are needed. Short-term oral etoposide was tolerated well in this patient with a  good clinical response. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research

ASCO 2018: highlights in HER2-positive metastatic breast cancer
SummaryAt the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjugates (ADCs) such as trastuzumab-deruxtecan and trastuzumab-duocarmazine suggest relevant clinical activity of these drugs in pretreated patients; in addition, these ADCs may offer activity in low HER2-expressing tumours as well. ZW25, a  bispecific HER2-directed antibody targeting the extracellular domains 2 and...
Source: Memo - Magazine of European Medical Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research

Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?
SummaryPreviously assumed to be rare, the prevalence of aggressive variants of prostate cancer has increased rapidly. This histologically heterogeneous group of cancers, including different forms of the neuroendocrine carcinoma of the prostate, share a  common clinical course associated with a poor response to androgen deprivation treatment and fatal prognosis. Currently, the most commonly used terms are aggressive variant of prostate cancer and treatment-related neuroendocrine prostate cancer. The best treatment of these tumors in clinical rout ine is still being debated. Here, we highlight the clinically most r...
Source: Memo - Magazine of European Medical Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research

Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context
ConclusionsIn the therapy of mCRC, predictive biomarker testing has shown to be effective and cost saving. For further improvement, a  strong research focus on predictive biomarkers is considered highly efficient to promote precision oncology by alleviating the pressure on the healthcare system. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - October 11, 2018 Category: Cancer & Oncology Source Type: research

A  rare parasitic infection: visceral leishmaniasis case after gastric cancer treatment
We present a  case ofVisceral Leishmaniasis (VL) in a  patient with gastric cancer treated with chemoradiotherapy. A 69-year-old man with gastric carcinoma had been treated with total gastrectomy, lymphadenectomy and postoperative radiotherapy with chemotherapy. Then 3 years after treatment, due to pancytopenia with progressive trombocytopenia and s plenomegaly, bone marrow examination was performed and Leishmania spp. amastigotes were diagnosed. When antibiotherapy was completed, splenomegaly was eliminated and the laboratory results became normal. VL should be kept in mind in the differential diagnosi...
Source: Memo - Magazine of European Medical Oncology - October 1, 2018 Category: Cancer & Oncology Source Type: research

Central nervous system-predominant Erdheim –Chester disease mimicking meningioma responding to BRAF inhibitor therapy: the importance of molecular diagnosis and targeted therapy in rare neoplastic disorders
We report a case of symptomatic, central nervous system (CNS)-predominant ECD initially presenting with CNS mass lesions mimicking meningiomas on imaging and prominent periorbital xanthogranulomas. CN S presentation of ECD, although not infrequent, bears particular significance here from a therapeutic point of view, since only partial debulking was possible owing to anatomical complexities. Radiological evaluation following surgery showed no significant change in the size of the lesions. Targete d therapy was commenced following histopathology, immunohistochemistry (IHC), and molecular testing, resulting in marke...
Source: Memo - Magazine of European Medical Oncology - September 20, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  3: Cytogenetic analysis (CA)
SummaryIn tumor cytogenetics, individual cancer cells are genetically analyzed, either conventionally by studying the mitotic chromosomes of dividing tumor cells from in vitro cultures (metaphase analysis; karyotyping) or molecularly by identifying specific DNA sequences or chromosomal regions in the nucleus of nondividing tumor cells in situ (interphase fluorescence in situ hybridization). In a  typical cytogenetic study, 20 metaphase cells and/or 200 interphase cells are microscopically investigated for visible somatic chromosome changes that might occur in a given neoplastic clone. The detection sensitivi...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a  rare case and review of literature
SummaryRuxolitinib is a  Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reacti vation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocomp...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  3: Cytogenetic analysis (CA)
SummaryIn tumor cytogenetics, individual cancer cells are genetically analyzed, either conventionally by studying the mitotic chromosomes of dividing tumor cells from in vitro cultures (metaphase analysis; karyotyping) or molecularly by identifying specific DNA sequences or chromosomal regions in the nucleus of nondividing tumor cells in situ (interphase fluorescence in situ hybridization). In a  typical cytogenetic study, 20 metaphase cells and/or 200 interphase cells are microscopically investigated for visible somatic chromosome changes that might occur in a given neoplastic clone. The detection sensitivi...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cryptococcal meningitis in an immunocompetent patient with primary myelofibrosis on long-term ruxolitinib: report of a  rare case and review of literature
SummaryRuxolitinib is a  Janus kinase (JAK) 2 inhibitor that is an effective therapeutic agent for primary myelofibrosis (PMF), which helps significantly to reduce constitutional symptoms and spleen size. However, this drug has significant immunomodulatory effects that may lead to various opportunistic infections. Reacti vation of tuberculosis and certain viral infections have been well documented. Although a few reports of patients with pulmonary cryptosporidiosis on ruxolitinib exist, an extensive literature review shows only one previously reported case of cryptococcal meningoencephalitis in an immunocomp...
Source: Memo - Magazine of European Medical Oncology - September 18, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease: how to manage and who is the right patient in GIST
SummaryGastrointestinal stromal tumors (GISTs) are a  rare type of cancer and a heterogeneous disease. The tyrosine kinase receptors KIT and the platelet-derived growth factor receptor alpha PDGFRA are the most common mutant genes of GIST. Mutation analysis is a diagnostic standard and is crucial for drug therapy with tyrosine kinase inhibitors (TK I). About 10% of patients already have metastases at first diagnosis. R0 resection is the only curative option in GIST and is therefore the therapy for localized tumors. In case of locally advanced primary tumors, neoadjuvant therapy should be offered. Recurrent, ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic breast cancer
SummaryOligometastatic disease characterizes a  distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several cas e series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defen...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Demystification of palliative care: what palliative care teams don ’t want you to think about them
SummaryThere is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct
We present the case of a  65-year-old woman with sublingual adenoid cystic carcinoma (ACC). Computed tomography (CT) sialography revealed an expansive process in the left sublingual gland accompanied with ipsilateral submandibular salivary duct obstruction. The head and neck tumor board recommended surgical and radiotherap y treatment. Presently, the patient is disease-free with no visible complications or signs of recurrence. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the management of liver metastases of advanced colorectal cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Current and evolving treatment strategies in adult immune thrombocytopenia
SummaryImmune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding —which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxic ity associated with treatment may outweigh its benefit. Most patients treated with standard first-line regimen of gl...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Long-term remission in advanced stage hepatocellular carcinoma? A  chance for cure?
SummaryLiver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a  rare event. This review summarizes data on radio...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Post SABCS local therapy and radiology
SummaryThis year there were three interesting oral presentations and several posters presenting important new data regarding local therapy (surgery and radiotherapy) as well as radiological aspects. This minireview is a  personal view of the clinically most relevant data in this respect with the following conclusions: A micrometastasis is no indication for axillary dissection. The number of involved sentinel lymph nodes predicts non-sentinel lymph node metastasis and should be taken into account regarding omittin g axillary dissection. Neoadjuvant chemotherapy reduces the risk of non-sentinel lymph node metastasi...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  2: flow cytometry
SummaryFlow cytometry (FC) plays an important role in the diagnosis and classification of hematological disorders and can analyze a  wide range of diagnostic samples. It is used in both diagnostic and follow-up testing, and is increasingly important in the detection of very small residual disease populations, i. e., minimal residual disease (MRD). Modern flow cytometers have the capability to analyze several thousands of cell s per second and to identify different cell populations by evaluating the expression of specific antigens (markers) along with light scatter properties of the cells. FC can precisely differenti...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.In a  retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial in vestigating ribociclib or placebo in combination with endocrine therapy ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Still making progress
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept ...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
SummaryPreoperative administration of chemotherapy is a  widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy a llows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes. A multitude of cl...
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Hemoglobinopathies —genetically diverse, clinically complex, and globally relevant
SummaryHemoglobinopathies represent the most frequent monogenic disorders worldwide. Migration during recent years led to a  profoundly increasing number of patients in countries where the indigenous population has not been affected. This short review will give an overview on etiology, pathogenesis, clinical features, diagnostics, and treatment of the most relevant hemoglobinopathies, i.e., the thalassemias and sickle c ell disease. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Nonmalignant hematology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Still making progress
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - September 1, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease: how to manage and who is the right patient in GIST
SummaryGastrointestinal stromal tumors (GISTs) are a  rare type of cancer and a heterogeneous disease. The tyrosine kinase receptors KIT and the platelet-derived growth factor receptor alpha PDGFRA are the most common mutant genes of GIST. Mutation analysis is a diagnostic standard and is crucial for drug therapy with tyrosine kinase inhibitors (TK I). About 10% of patients already have metastases at first diagnosis. R0 resection is the only curative option in GIST and is therefore the therapy for localized tumors. In case of locally advanced primary tumors, neoadjuvant therapy should be offered. Recurrent, ...
Source: Memo - Magazine of European Medical Oncology - August 28, 2018 Category: Cancer & Oncology Source Type: research

Long-term remission in advanced stage hepatocellular carcinoma? A  chance for cure?
SummaryLiver resection, transplantation, and local ablation are potential curative treatment options but can only be offered to patients with early stage hepatocellular carcinoma (HCC). Patients with macrovascular tumor invasion and extrahepatic metastases are candidates for palliative systemic therapies. Achieving radiological complete response can be associated with long-term remission and excellent outcome. However, despite recent advancements in the medical treatment of advanced stage HCC, complete remission with available systemic treatment options still remains a  rare event. This review summarizes data on radio...
Source: Memo - Magazine of European Medical Oncology - August 24, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
This article reviews the clinically most relevant presentations at the San Antonio Breast Cancer Symposium (SABCS) 2017 on the topics lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis.In a  retrospective analysis of the Women’s Health Initiative Observational Study, a reduction in the body mass index (BMI) of at least 5% within 3 years significantly reduced the risk of breast cancer compared to women with a stable weight (HR 0.77; 95% CI 0.78–0.98). In the MONALEESA-7 trial in vestigating ribociclib or placebo in combination with endocrine therapy ...
Source: Memo - Magazine of European Medical Oncology - August 21, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
SummaryIn the areas of chemotherapy, targeted therapy and immunotherapy, several interesting and clinically relevant data were presented at the 2017 San Antonio Breast Cancer Symposium (SABCS). This short review focuses on dose-dense and/or sequential administration of adjuvant chemotherapy, provides an update on targeted therapies for HER2-positive and triple-negative breast cancer and summarizes new results in the field of immunotherapy. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Thrombotic thrombocytopenic purpura
SummaryThrombotic thrombocytopenic purpura (TTP) is a  clearly defined entity of the thrombotic microangiopathies (TMA), a heterogeneous group of disorders characterized by microangiopathic hemolytic anemia with red cell fragmentation, thrombocytopenia and organ dysfunction due to disturbed microcirculation. TTP is characterized by a severe deficien cy of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), an enzyme responsible for physiological cleavage of von Willebrand factor (VWF). Organ dysfunction can be severe and life-threatening, and imme...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic breast cancer
SummaryOligometastatic disease characterizes a  distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are reported after locoregional treatment of the primary tumor and all metastatic sites in several cas e series; however, unlike other tumor entities, prospective data are lacking. Furthermore, tumor eradication by excellent systemic anticancer therapy with novel chemotherapies and targeted agents can lead to long-term survival. In addition, reactivation of the host immune defen...
Source: Memo - Magazine of European Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Current and evolving treatment strategies in adult immune thrombocytopenia
SummaryImmune thrombocytopenia (ITP) is an acquired autoimmune phenomenon resulting in low platelet count and increased bleeding risk. Goals of upfront management include prompt control of severe bleeding —which is rare—as well as induction and maintenance of a hemostatic platelet count. Thus, optimal management of ITP patients is often challenging and requires a highly individualized approach. Many patients may not suffer significant bleeding despite severe thrombocytopenia and the risk of toxic ity associated with treatment may outweigh its benefit. Most patients treated with standard first-line regimen of gl...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

SABCS 2017 pathology: from bench to bedside
SummaryThe 40th  International San Antonio Breast Cancer Symposium offered a multifaceted platform for the presentation of several innovative therapeutic approaches. The results of these preclinical and clinical studies provided insight into the development of novel therapy concepts from the laboratory bench to t he bedside of breast cancer patients. One main focus of last year’s symposium was the search for synergisms and opportunities for collaboration between basic research scientists and investigators in drug development. Highlights of these topics included preclinical data on selective estrogen recept ...
Source: Memo - Magazine of European Medical Oncology - August 15, 2018 Category: Cancer & Oncology Source Type: research

Report from the ASCO 2018 Congress, Chicago, June 1st-5th, 2018
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - August 9, 2018 Category: Cancer & Oncology Source Type: research

Nonmalignant hematology
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 25, 2018 Category: Cancer & Oncology Source Type: research

ASCO 2018: highlights of urothelial cancer and prostate cancer
SummaryProstate cancer and urothelial carcinoma are the two most common urological cancers. The aim of this short review is to highlight abstracts from this year ’s ASCO Annual Meeting. The phase III SPCG-13 trial showed no difference in biochemical disease-free survival by the addition of docetaxel after primary radiation therapy of localized high-risk prostate cancer. In bone dominant metastatic castration resistant prostate cancer, the phase II radium -223 dose escalation study concluded that the currently used dose with 6 cycles of 55 kBq/kg remains the standard of care. The PARP inhibitor olapar...
Source: Memo - Magazine of European Medical Oncology - July 24, 2018 Category: Cancer & Oncology Source Type: research

Adenoid cystic carcinoma of the sublingual salivary gland obstructing the submandibular salivary gland duct
We present the case of a  65-year-old woman with sublingual adenoid cystic carcinoma (ACC). Computed tomography (CT) sialography revealed an expansive process in the left sublingual gland accompanied with ipsilateral submandibular salivary duct obstruction. The head and neck tumor board recommended surgical and radiotherap y treatment. Presently, the patient is disease-free with no visible complications or signs of recurrence. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 20, 2018 Category: Cancer & Oncology Source Type: research

Current concepts and future directions in neoadjuvant chemotherapy of breast cancer
SummaryPreoperative administration of chemotherapy is a  widespread treatment approach in early stage breast cancer whenever chemotherapy is indicated in principle. In addition, neoadjuvant treatment is today regarded as the preferred way of delivering systemic therapy in triple-negative and HER2-positive breast cancer. While preoperative chemotherapy a llows for disease downstaging and increases breast conservation rates, achieving pathologic complete remission (pCR) is usually regarded as the most pertinent aim as pCR predicts for improved long-term outcome in high-risk breast cancer subtypes. A multitude of cl...
Source: Memo - Magazine of European Medical Oncology - July 19, 2018 Category: Cancer & Oncology Source Type: research

Demystification of palliative care: what palliative care teams don ’t want you to think about them
SummaryThere is robust data that palliative care is prolonging life while there are still prejudices towards this discipline that have to be demystified. Patients, relatives and caregivers benefit from the concept of early integration of palliative care and therefore, palliative care should not be mainly regarded as end-of-life care. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Cure in metastatic disease
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - July 17, 2018 Category: Cancer & Oncology Source Type: research

Educational no.  2: flow cytometry
SummaryFlow cytometry (FC) plays an important role in the diagnosis and classification of hematological disorders and can analyze a  wide range of diagnostic samples. It is used in both diagnostic and follow-up testing, and is increasingly important in the detection of very small residual disease populations, i. e., minimal residual disease (MRD). Modern flow cytometers have the capability to analyze several thousands of cell s per second and to identify different cell populations by evaluating the expression of specific antigens (markers) along with light scatter properties of the cells. FC can precisely differenti...
Source: Memo - Magazine of European Medical Oncology - June 25, 2018 Category: Cancer & Oncology Source Type: research

My burning issues in the management of liver metastases of advanced colorectal cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - June 14, 2018 Category: Cancer & Oncology Source Type: research

Management of adverse events related to checkpoint inhibition therapy
SummaryIO treatments (immuno-oncology treatments) have become reality and are now daily practice or, in some cases, a daily challenge. New recommendations are being made with the prime purpose of increasing alertness and awareness as well as emphasizing standard operating strategies to deal with immune-related adverse events (ir-AEs) in patients treated with immune checkpoint inhibitors (ICI). This brief review refers to systemic reviews, guidelines and meta-analyses, randomized controlled trials and case series published from 2000 to the present. Existing recommendations for optimal management of toxicities vary according...
Source: Memo - Magazine of European Medical Oncology - June 12, 2018 Category: Cancer & Oncology Source Type: research